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Abstract 
Dexmedetomidine (DMET) is a sedative, analgesic and anxiolytic with minimum adverse 
respiratory effects. An LC-MS/MS bioanalytical method has been developed and validated to 
accurately measure DMET concentrations in samples of human plasma. The method 
overcomes difficulties in the extraction and quantification of DMET due to the fact that it 
binds strongly to glass and plastic tubes, as well as solid phase extraction (SPE) cartridges. 
Human plasma (50 µL) was mixed with the internal standard (IS) (DMET-d4) solution (100 
µl) and 0.1% formic acid (50 µL) and extracted using Oasis HLB 1 CC (30 mg) solid phase 
extraction (SPE) cartridges (Waters®). The glass tubes were coated with bovine serum 
albumin (BSA) 0.5% (20 µL) before eluting DMET and the IS. After evaporation under 
nitrogen at room temperature, the analytes were reconstituted in 20% acetonitrile in 0.1% 
formic acid in water and transferred to silanized glass vials. An electrospray ionisation (ESI) 
mass spectrometry method in positive mode was created and the precursor/product 
transitions (m/z) were 201.1 → 95.0 (DMET) and 204.9 → 99.0 (IS). The method was robust 
and fully validated based on the 2012 EMEA guideline for bioanalytical method validation in 
the concentration range of 0.5-20 ng/mL. Using this assay, we showed that DMET binds 
strongly to Extracorporeal Membrane Oxygenation (ECMO) circuits, consistent with 
expectations for small lipophilic compounds. 
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1. Introduction 
Dexmedetomidine (DMET) is a potent sedative and analgesic drug with high affinity for α-2-
receptors which has been approved by the United States Food and Drug Administration 
(FDA) for use in Intensive Care Units [1]. DMET is a lipophilic small molecule (Mw=200 
g/mole, Log P=3.2) with a large volume of distribution (1.0 L/kg) and it has been reported to 
be adsorbed to polyvinyl chloride (PVC) tubing during circulation of patients´ blood through 
extracorporeal membrane oxygenation (ECMO) circuits [2].  
There are several published LC-MS/MS methods for the quantification of DMET with the 
focus of these methods being on reducing sample volume and improving the lower limit of 
quantification (LLOQ) [3-9]. Most of these assays require evaporation of extracted samples 
after Liquid-Liquid Extraction [3-4] or SPE [5-7] necessitating long periods of exposure to the 
plastic or glass surfaces which can potentially adversely affect the performance of the assay. 
More recently, a protein precipitation method using 200 µL acetonitrile added directly to 
plasma samples (100 µL) without any evaporation step and a very short run-time, was 
published [8]. However, this approach produces ‘dirty’ samples and so is only suitable for 
low turn-over laboratories with small batches as it requires extensive washing of the HPLC 
system between sample analysis batches. 
The aim of this study was to develop and fully validate an LC-MS/MS bioanalytical method to 
improve the quantification of DMET in samples of human plasma. This assay was used to 
estimate the extent of adsorption of DMET onto ECMO circuits. In this paper, we explain the 
main issues overcome during method development and validation for quantification of DMET 
concentrations in samples of human plasma.   
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2. Experimental 
2.1 Materials and Reagents 
DMET and DMET-d4 were obtained from Toronto Research Chemicals (North York, Ontario, 
Canada). Formic acid (99%) was purchased from Univar (Sydney, NSW, Australia). HPLC 
grade methanol and acetonitrile were bought from Lab Scan (Brisbane, QLD, Australia). 
Human blank plasma was obtained from BioCore Pty Ltd (Sydney, NSW, Australia). SPE 
cartridges; Oasis HLB 1 CC (30 mg) were purchased from Waters (Rydalmere, NSW, 
Australia). 
2.2 Chromatographic Conditions 
Liquid chromatography and pump gradients were created using Symbiosis Pro software for 
analyst (V 2.1.0.0) and the mass spectrometer controlling software (Analyst 1.6.1). An HPLC 
column (X-Terra® MS C18, 2.1 mm x150 mm, 5 µm; Waters, Sydney, NSW, Australia), and 
Phenomenex Security Guard C18 column (Phenomenex, Sydney, Australia) were used for 
chromatographic separation of the DMET and DMET-d4. The column and autosampler 
temperatures were set at 50°C, and 4 °C, respectively. The mobile phase comprised solvent 
A (0.1% formic acid in water) and solvent B (acetonitrile) and the mobile phase flow rate was 
0.5 mL/min. The mobile phase elution program was started at 20% mobile phase B and 
continued until 1:00 min. Then, the flow increased to 90% B at 2:50 min and stayed constant 
for 1 min before dropping to 20% B at 3:40 min, followed by a 2 min equilibrium period. 
 
2.3 Mass Spectrometry Conditions 
Mass spectrometry detection was carried out in ESI positive mode using a Q-Trap 5500 (AB-
Sciex, Concord, Ontario, Canada) LC-MS/MS instrument. The highest abundant product 
ions which had no interference by plasma matrix components were selected for the 
quantification of DMET and the internal standard (IS).  
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2.4 Preparation of standards, calibration curves and quality control samples 
Stock solutions of DMET and DMET-d4 were prepared in 50% methanol in water at a 
concentration of 1 mg/mL and were stored frozen at −20 °C. Working solutions were made in 
50% methanol in water to achieve a concentration of 10 µg/mL. For making calibration 
standards, the working solution (10 µg/mL) was diluted in 50% methanol in water to make 
standard solutions of 20, 16, 10, 5, 3, 1, 0.5 ng/mL. Aliquots of the standard solutions (50 
µL) were spiked in 50 µL aliquots of pooled human plasma and mixed with IS solution 10 
ng/mL (100 µL) and 0.1% formic acid in water (50 µL).  
 
For QC preparations, aliquots of the stock solution of DMET in 50% methanol in water (100 
µg/mL) were serially diluted using 50% methanol in water to prepare four QC solutions. 
Aliquots of 100 µL of those solutions were spiked in 5 mL of pooled human plasma to 
achieve final concentrations of 15 (QCH), 10 (QCM), 1.5 (QCL) and 0.5 (QCLLOQ) ng/mL. 
QCs prepared in pooled human plasma were aliquoted in small volumes (200 µL) and stored 
in frozen at -20 °C. 
 
2.5 Sample preparation 
Plasma samples and QCs (50 µL) were mixed with 100 µL aliquots of the IS (DMET-d4) 
solution at 10 ng/mL in 0.1% formic acid in water) and 50 µl aliquots of 0.5% formic acid in 
water, and vortexed before loading onto SPE cartridges. The SPE cartridges were 
conditioned with 1 mL aliquots of methanol and 1 mL aliquots of 0.1% formic acid in water 
prior to loading of the plasma samples. After plasma sample loading, the cartridges were 
washed with 30% methanol in water (1 mL). Before elution of the analytes of interest, 
aliquots of BSA 0.5% in water were added to each tube (20 µL) and vortexed. Then, DMET 
and the IS were eluted using 1 mL of 5% isopropanol, 10% acetonitrile and 85% methanol. 
Samples were evaporated using nitrogen at room temperature and reconstituted in 20% 
acetonitrile in 0.1% formic acid in water and transferred to silanized glass tubes with crimped 
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caps and placed in the autosampler. Thereafter, 10 µL aliquots were injected into the LC-
MS/MS system. 
 
 2.6 Assay performance 
The method was validated based upon the criteria specified by EMEA guideline on 
bioanalytical method validation, February 2012 [10].   
 
3. Results and Discussion 
3.1 Method development  
SPE is preferable to liquid-liquid extraction of plasma samples in terms of minimising the use 
of toxic organic solvents. Protein precipitation is good when only small numbers of samples 
need to be analysed quickly because it negatively affects the life-time of the HPLC column 
and the whole LC-MS/MS system. In the present method, a relatively high percentage of 
methanol in water (30% methanol in water) was used to wash the SPE cartridges prior to 
analyte elution and this resulted in very clean samples without losing the analytes. 
Acidification of plasma samples before SPE extraction can reduce the lipophilicity of the 
DMET (Log D= 2.3 at pH=3) and therefore make it easier for elution from the SPE 
cartridges. 
 
Initially, we used tolazoline as IS but it was unsatisfactory because its elution pattern from 
the cartridges was differed from that of DMET. As noted by Lee et al [5], tolazoline needs to 
be added after completion of SPE which compromise the role of IS as a correction factor for 
loss of analytes during the extraction. Dissimilar physicochemical properties between 
tolazoline and DMET are also underscored by the very different retention time of these two 
analytes [5]. Cui et al [3] used testosterone as the IS for the validation of the DMET assay in 
ewe plasma samples. However, testosterone is not suitable for the analysis of human 
samples due to the endogenous levels of the hormone in human blood. Using DMET-d4 with 
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similar affinity for SPE cartridges and the HPLC column enabled a robust SPE extraction 
method to be devised.  
 
A significant issue with extraction of DMET from samples of human plasma was its binding 
to all tubes with a higher binding tendency to plastic compared with glass tubes which this 
problem is exacerbated at low concentrations. Although QCs stored in the freezer (both -20 
°C and -80 °C) for only a few weeks may pass the accuracy criteria, longer periods of frozen 
storage led to a significant reduction in the content of DMET in QCL and QCLLOQ. This is 
likely due to adsorption of the analyte to the plastic tubes during the storage. When 
the pure standards (0.5-10 ng/mL) were diluted in plastic tubes, evaporated to 
dryness at room temperature and reconstituted in 500 µL of 0.1% formic acid in 
water, the peak areas of the standards were 15-20% smaller than what was 
observed for the same solutions in glass tubes (this was most marked at low 
concentrations). Furthermore, for the Low standard (1.5 ng/mL) spiked in plasma 
and extracted, the peak area was 7-fold larger than that for the same standard in 
solution which may be due to the presence of plasma proteins in minimising the 
adsorption of the analyte to the tubes’ surfaces. 
 
To address this issue, we used glass tubes containing a small volume (20 µL) of BSA 0.5% 
in water to collect the SPE elution solvent containing DMET and DMET-d4. DMET working 
solutions were diluted in 50% methanol in water before spiking into the ‘blank’ plasma 
samples as it is well-known that organic solvents and plasma proteins can minimise analyte 
binding to tubes. After extraction and evaporation of the organic solvents, analytes were 
reconstituted in 20% acetonitrile in water and we used silanized glass vials to minimise 
binding.  
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
DMET is an anaesthetic drug that is similar to thiopental and propofol [11] in that the analyte 
is lost during evaporation at high temperature. Herein, we found that the DMET 
concentrations eluted from the SPE cartridges were stable when elution solvent was 
evaporated under a stream of nitrogen and at room temperature.  
 
3.2 MS conditions 
For DMET and DMET-d4, positive ion electrospray ionisation in MRM mode produced the 
best results. The optimised MS parameters were as follows: spray voltage 4500 V, turbo gas 
temperature 300°C, curtain gas pressure 30 psi, nebulizer gas pressure 50 psi, heater gas 
pressure 50 psi and collision gas pressure set at Medium. The collision energy was 
optimised at 25 V for both DMET and DMET-d4. The cell exit potentials (CXP) were 14 for 
DMET and 55 for DMET. The declustering potential (DP) were set at 66 and 86 for DMET 
and DMET-d4, respectively. For quantification, the transitions of the parent ions to the 
product ions were 201.1 → 95.0 m/z for DMET and 204.9 → 99.0 for DMET-d4.  
 
3.3 Assay performance 
The calibration curves for DMET were linear when assessed on 6 separate occasions using 
a linear regression model weighted by 1/x using Analyst® software (AB Sciex, Concord, 
Ontario, Canada). The precision and accuracy of the assay of DMET was within the required 
ranges (all less than 10%) and the mean regression coefficients (r2) were all greater than 
0.9956 (Table 1).  
 
The signal to noise ratio for DMET was 50 (average of 18 replicates of LLOQ). It is clear 
from the signal to noise ratio, and the accuracy and precision of the method at the LLOQ that 
the sensitivity of the method could potentially be improved 10-fold, if required. However, the 
proposed application of this assay to the quantification of DMET concentrations in samples 
collected from an ex-vivo model of ECMO, does not require such a high level of assay 
sensitivity. DMET is well ionised in the mass spectrometer detector and therefore low 
AC
CE
PT
ED
 M
AN
US
RI
PT
9 
 
concentrations at 5 pg/mL are easily detectable [5, 9]. By increasing the sample and 
injection volumes, and decreasing the reconstitution solvent volume, the sensitivity can be 
potentially increased by more than 100-fold although the binding of DMET to the tubes as 
such low concentrations may be problematic.  
 
The within-run and between-run accuracy and precision were assessed using LLOQ, low, 
medium and high QCs (Table 2). The precision and accuracy of six replicates for each of the 
QCs were within the ±15% range and ± 20% at the LLOQ. The accuracy and precision of the 
diluted QCs (QCs at 5 times the highest standard concentration of DMET (100 ng/mL) that 
were diluted 1 in 10 with free blank plasma) were 90.5% and 2.7%, respectively. 
 
The recovery of DMET was high and reproducible in three spiked pooled plasma samples at 
concentrations of 1.5, 10 and 15 ng/mL compared with the same concentrations of pure 
DMET dissolved in aqueous solutions (0.1% formic acid in water). The average recoveries 
for DMET and the IS (10 ng/mL) were 86% and 85%, respectively.  
 
The matrix factor (MF) (the ratio of the peak area in the presence of matrix (measured by 
analysing blank matrix after extraction and then spiked with DMET, relative to the peak area 
in the absence of matrix) for the individual human plasma samples spiked with DMET at 1.5 
and 15 ng/mL, and DMET-d4 at 10 ng/mL was calculated. The IS normalised MF was 
calculated by dividing the MF of DMET by the MF of DMET-d4. The CV% of the IS-
normalised MF calculated from 6 different lots of human plasma were 4% and 3.8%, 
respectively. 
 
No significant peak (≥20% of the LLOQ and 5% of the IS) was detected in blank samples 
injected after the ULOQ samples. Adding 3 needle wash solvents effectively washed the 
system between samples and reduced the carry-over. 
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Selectivity was tested using 6 sources of human plasma samples (Li-heparin as the anti-
coagulant) which were analysed using the described method. The resulting chromatograms 
were checked for peaks that might interfere with the detection of the analyte of interest or the 
IS. No interfering peak (less than 20% of the LLOQ response, and <5% of the IS response) 
was detected when 6 individual blank plasma and 6 individual blank plasma spiked with IS 
were analysed using the described method. 
 
DMET QCs at low and high (n=6) concentrations were stable after 4 cycles of freeze and 
thaw from −20 °C to room temperature, 112 days at -20 °C and 5 h at room temperature. 
Samples stored in the autosampler at 4 °C were stable for at least 48 h (Table 3). Stock 
solutions of DMET in 50% methanol in water were stable at -20 °C for at least 77 days. Our 
stability data is comparable with studies in which samples were kept at -20 °C and had the 5 
h short-term stability and 4 freeze and thaw cycles [6, 8]. 
 
3.4 Assay application 
To study the sequestration of DMET in ECMO circuits, four identical ECMO circuits that were 
filled with human whole blood were spiked with DMET at therapeutic concentrations. Serial 
blood samples were collected from the ECMO circuits over 24 hours and the DMET 
concentrations were quantified using the described assay. Details of the ex-vivo experiment 
have been published previously [12]. The collected samples from ECMO circuits and 
controls were analysed using the assay developed and validated in this paper. The data are 
presented in Fig 2. Sequestration of DMET to both old and new ECMO circuits was reported 
previously [2] consistent with expectations for small lipophilic compounds [13]. 
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Fig 1. Representative peaks of A. DMET standard 3 ng/mL, B. IS (10 ng/mL), C. LLOQ 0.5 
ng/mL and D. double blank. 
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Fig 2. Temporal decrease in the concentration of DMET in ECMO circuits (concentration ± 
SEM) 
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Table 1. Linearity of DMET standard curves 
 
         
*Y=ax+b 
 
 
 
 
 
 
 
 
 
 
 
Standard 
Concentration 
(nominal, ng/mL) 
Measured concentrations 
(mean ± SEM, n=6) 
Precision (%) Accuracy (%) 
0.5 0.53 9.220 93.67 
1 0.97 7.601 103.15 
3 2.95 3.842 101.69 
5 4.98 4.436 100.36 
10 10.05 2.606 99.53 
16 16.00 2.910 100.01 
20 20.05 1.356 99.74 
a* 
0.107 
   
r2 0.9956 
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 Table 2. The within-run and between-run accuracy and precision of the DMET QCs. 
 
 Within-Run 1 (n=6) Within-Run 2 (n=6) Within-Run 3(n=6) Between-Run (n=3) 
QC Concentration Accuracy Precision Accuracy Precision Accuracy Precision Accuracy Precision 
LLOQ (0.5 ng/mL) 102.1 7.9 95.8 14.7 92.9 17.9 97.3 13.2 
Low (1.5 ng/mL) 90.7 3.9 92.8 11.7 112.0 11.0 98.5 13.6 
Med (10 ng/mL) 85.9 1.5 104.6 5.5 97.7 8.6 96.0 10.1 
High (15 ng/mL) 87.0 4.6 97.4 4.9 94.8 4.1 93.1 6.5 
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Table 3. Stability of the DMET QCs after 4 cycles of freeze and thaw, 5h at room temperature and 112 days at -20 °C based on the accuracy 
and precision of calculated concentrations  
  
F&T Stability (4 cycles) 
(n=6) 
Room Temperature Stability (5h) 
(n=6) 
Frozen Storage Stability 
(112 days at -20 °C) 
(n=6) 
QCL 
(1.5 ng/mL) 
Accuracy 100.8 102.4 102.2 
Precision 5.9 6.8 3.7 
QCH 
(15 ng/mL) 
Accuracy 99.9 111.7 98.3 
Precision 5.9 4.9 3.3 
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